Viagra was originally developed to treat high blood pressure and chest pain caused by reduced blood flow to the heart, but over the past three decades it has become the world's best-known therapy for erectile dysfunction. ...
Jul 21, 2026
0
94
Chronic, low-grade inflammation in the body—a phenomenon known as "inflammaging" because it increases with age—has been linked to many of today's leading causes of illness and death, including cancer, heart disease, metabolic ...
Jul 21, 2026
0
59
Researchers have uncovered a clue to why immune checkpoint inhibitors—cancer therapies that release the immune "brakes" exploited by tumors to evade attack—show limited efficacy in some brain tumors. A KAIST research team ...
Jul 20, 2026
0
15
One of the biggest challenges in cancer research has been linking the "big picture" seen in medical scans with the microscopic biology that drives tumor growth and dictates how patients respond to treatment. Now, by combining ...
Jul 17, 2026
0
285
A new Northwestern Medicine study has uncovered how a key immunoregulatory receptor plays an unexpected dual role in promoting T-cell exhaustion during chronic infection and cancer, according to findings published in the ...
Jul 16, 2026
0
36
Researchers at Kanazawa University report that blood-based gene expression tests may enable early pancreatic cancer screening and improve long-term survival.
Jul 16, 2026
0
18
Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based ...
Jul 16, 2026
0
7
Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular ...
Jul 15, 2026
0
9
Residential context has a stronger association with survival for Black than White women with epithelial ovarian cancer (EOC), according to a study published online Aug. 10 in JAMA Network Open.
2 hours ago
0
0
Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.
3 hours ago
0
1
